(0) / view cart / checkout  
  Company Profiles
  Country Analyses
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
Aerospace, Defense
Business Services
Company Reports
Consumer Goods
Energy, Environment
Food & Beverages
Medical Devices
Sales & Marketing
Travel, Entertainment
Home > In Vitro Diagnostics DNA Probes/Biochips >  DNA Sequencing Equipment and Services Markets

DNA Sequencing Equipment and Services Markets


This report, DNA Sequencing Equipment and Services Markets, represents the third time Kalorama has detailed the market for DNA sequencing systems, as well as consumables used in sequencing and sequencing services. Much has changed since the last Kalorama edition of this report. More companies are offering sequencing services. The market was moving in a relatively linear manner for about two years in terms of competition, with no disruptive technologies or business models introduced. After a period of relative stability, the market has seen major developments in 2011 and 2012. The introductions of the Ion Torrent PGM, PacBio RS and MiSeq have changed the situation in the market, with more new technologies expected from Ion Torrent as well as Oxford Nanopore.

DNA sequencing can be defined as any biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and discovery, which created a brisk market for sequencing systems that perform this work.   The growing availability of vast amounts of annotated sequence data permits life science researchers to undertake a much wider range of experiments.As part of the report’s coverage, the following data is provided:

  • Current Market Estimate
  • Historical Market Data since 2006
  • Forecast to 2016
  • Review of Major Company Sequencing Products
  • The Status of Next Gen Systems
  • Clinical Applications vs. Research Applications in Sequencing
  • Litigation and Intellectual Property Developments
  • Deals in the Industry
  • Market Share of Major Players
  • Challenges and Strategic Recommendations
It is the beginning of a revolutionary time for the life sciences. Pricing changes, purchases by first-time users. Consortia, initiatives, a Groups have been organizing to sequence hundreds or thousands of individuals, species, tumors and the like in a short period of time – the 1,000 Genomes Project, the 1,001 Arabidopsis Project, and many others, many of which are covered in the Trends section of the report. Longer-term, questions still remain for broad areas that are seen as large opportunities, such as disease prevention and diagnostics.
The market remains volatile, but some patterns have been stabilizing in recent years.  The report uses primary and secondary research to present market watchers with an assessment of the marketplace in 2012.  As part of its coverage, the report profiles the following companies:
  • 454 Life Sciences (Roche)
  • Complete Genomics
  • Illumina
  • Life Technologies
  • Pacific Biosciences

As the report details, the science is constantly evolving, and trends could work against DNA sequencers for some reason. Microarrays are still more cost-effective for GWAS, but given the trends in the science and the sequencing costs, it seems inevitable that will change. Further complicating things, somatic mutations, viral genome insertions, and epigenetic changes continue throughout life. The competition has been brutal as systems are constantly improved and new products are appearing with increasing frequency.  Longer-term, new segments in diagnostics and industry are likely to open up further. The pharmaceutical industry is likely to be a growing segment, due to personalized medicine and other genomics-related projects. 

To order sections of this report, contact Client Services

Local PDF: $3995.00
Other Formats: Global PDF, DataPack
VPGMarketResearch.com © Copyright 2015. all rights reserved. Web Design by Spida Design  
  Close  X